FDA: Naproxen Cardiovascular Risk Not Lower than Other NSAIDs.

At an FDA panel meeting held February 11, an advisory committee voted 16-9 to recommend against changing the label of naproxen-containing therapies. The committee concluded that there was insufficient evidence that naproxen carried a lower risk of cardiovascular thrombotic events than other NSAIDs such as ibuprofen and Pfizer's Celebrex (celecoxib). Read a news report here.


Related Content